Previous 10 | Next 10 |
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: IYH: Healthcare Dashboard For May
CINCINNATI, May 17, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of its new Air-Dryable™ Direct DNA qPCR Plant Mix. This unique Mix is specifically designed to ...
The following slide deck was published by Meridian Bioscience, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Meridian Bioscience, Inc. 2021 Q2 - Results - Earnings Call Presentation
Meridian Bioscience, Inc. (VIVO) Q2 2021 Earnings Conference Call May 07, 2021, 10:00 ET Company Participants Charles Wood - VP, Corporate Strategy, Business Development & IR John Kenny - President, CEO & Director Bryan Baldasare - EVP, CAO, CFO & Secretary Conference Call Partici...
Image source: The Motley Fool. Meridian Bioscience Inc (NASDAQ: VIVO) Q2 2021 Earnings Call May 7, 2021 , 10:00 a.m. ET Operator Continue reading For further details see: Meridian Bioscience Inc (VIVO) Q2 2021 Earnings Call Transcript
Meridian Bioscience (VIVO): FQ2 Non-GAAP EPS of $0.57 beats by $0.09; GAAP EPS of $0.61 beats by $0.18.Revenue of $85.26M (+48.8% Y/Y) misses by $1.98M.FY2021 Net Revenues:Consolidated $305 million to $335 million ($326.24M consensus)Diagnostics segment $125 million to $135 millionLife Scienc...
CINCINNATI, May 07, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO) today announced financial results for the second quarter ended March 31, 2021. Second Quarter 2021 Highlights (Comparison to Second Quarter Fiscal 2020): Consolidated net revenues of $85.3 mi...
CINCINNATI, April 28, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today the launch of the Lyo-Ready™ DNA LAMP Mix, specifically designed for accelerating the development of amb...
CINCINNATI, April 19, 2021 (GLOBE NEWSWIRE) -- Meridian Bioscience, Inc. (NASDAQ: VIVO), a provider of diagnostic testing solutions and life science raw materials, will report second quarter fiscal 2021 financial results Friday, May 7, 2021. Jack Kenny, Chief Executive Officer, and Br...
Meridian Bioscience benefited from a windfall due to the Covid-19 pandemic, resulting in the growth of its Life Science segment. There will be a market for Covid testing in the post-Covid world, but the eventual market size of Covid testing remains uncertain. Its Diagnostic segmen...
News, Short Squeeze, Breakout and More Instantly...
Meridian Bioscience Inc. Company Name:
VIVO Stock Symbol:
NASDAQ Market:
Meridian Bioscience Inc. Website:
Net revenue for Q4 2022 was $7.1 million, a 15% increase from prior quarter. Net revenue for 2022 was $25.4 million, a 2% increase compared to 2021. Net losses have decreased by 21.2 million in 2022, a 30% decrease from the prior year. The Company signed a definitive agreemen...
Toronto, Ontario--(Newsfile Corp. - March 24, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that it has obtained a final court order (the " Final Order ") from the Ontario Superior Court of Justice (Commercial List) approving the previously announced pl...
Toronto, Ontario--(Newsfile Corp. - March 21, 2023) - VIVO Cannabis Inc. (TSX: VIVO) (OTCQB: VVCIF) (" VIVO ") is pleased to announce that, at the special meeting of the shareholders of VIVO (the " Shareholders ") held today (the " Meeting "), the Shareholders approved (i) a special resolutio...